ACM
RLMD icon

ACT Capital Management’s Relmada Therapeutics RLMD Stock Holding History

ACT Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,700
Closed -$791K – 129
2021
Q2 		$791K Buy
+24,700
New +$858K 0.41% 45

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACT Capital Management's RLMD Position: Q3 2021 in Review

ACT Capital Management sold out of Relmada Therapeutics (RLMD) in Q3 2021, closing a stake of 24,700 shares — an estimated $791K sold.

ACT Capital Management first reported a position in RLMD in Q2 2021 and held it in 1 quarter. The position peaked at $791K in Q2 2021. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

  • ACT Capital Management reported no remaining Relmada Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 24,700 Relmada Therapeutics shares in Q3 2021, an estimated $791K.
  • ACT Capital Management first reported a position in Relmada Therapeutics in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Relmada Therapeutics position peaked at $791K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.